Trinity Biotech (NASDAQ:TRIB – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, Zacks reports.
Trinity Biotech Stock Performance
NASDAQ:TRIB traded down $0.06 during mid-day trading on Tuesday, reaching $0.62. The stock had a trading volume of 468,821 shares, compared to its average volume of 199,786. The firm has a market capitalization of $2.22 million and a price-to-earnings ratio of -0.16. Trinity Biotech has a twelve month low of $0.50 and a twelve month high of $3.44. The business has a 50 day simple moving average of $0.65 and a 200 day simple moving average of $0.75.
Wall Street Analyst Weigh In
Separately, Weiss Ratings downgraded Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce”.
Hedge Funds Weigh In On Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Citadel Advisors LLC grew its holdings in Trinity Biotech PLC (NASDAQ:TRIB – Free Report) by 196.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,384 shares of the company’s stock after buying an additional 26,084 shares during the quarter. Citadel Advisors LLC owned about 1.10% of Trinity Biotech worth $41,000 at the end of the most recent quarter. 78.97% of the stock is currently owned by institutional investors.
About Trinity Biotech
Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.
The company’s product portfolio includes a comprehensive array of assays and instrumentation.
See Also
- Five stocks we like better than Trinity Biotech
- Goldman’s S&P 500 Target Looks More Reachable After the Latest Rally
- 3 Stocks Diluting Shareholders to Fund Big Long-Term Opportunities
- Father’s Day Investing: 3 Stocks Built for Long-Term Returns
- This Golden Cross Could Send Urban Outfitters to New Highs
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
